SPONSOR
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Total Trials
1
Recruiting
1
Phases
Phase 1, Phase 2
Conditions studied: Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast CarcinomaTriple Negative Breast Cancer (TNBC)
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. is a clinical research sponsor with 1 registered studies on ClinicalTrials.gov, of which 1 are actively recruiting participants. Research covers conditions including Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC).
The trial portfolio spans Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
How many clinical trials has Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. sponsored?
ClinicalMetric currently tracks 1 clinical trials sponsored by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc., of which 1 are actively recruiting participants. These trials cover conditions including Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. research focus on?
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. clinical trials span Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, and additional conditions. The research pipeline includes Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. clinical trial?
To participate in a Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. trials with current recruitment status updated daily.
Clinical Trials by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology